DK0939626T3 - Galenisk form til forlænget frigivelse af milnacipran - Google Patents

Galenisk form til forlænget frigivelse af milnacipran

Info

Publication number: DK0939626T3
Authority: DK; Denmark
Prior art keywords: hours; milnacipran; mum; dose released; dose
Prior art date: 1996-08-28

Application number

DK97938949T

Other languages

Danish (da)

English (en)

Inventor

Bruno Paillard

Eric Goutay

Jean-Louis Avan

Jooel Bougaret

Original Assignee

Pf Medicament

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-28

Filing date

1997-08-26

Publication date

2002-05-27

1997-08-26 Application filed by Pf Medicament filed Critical Pf Medicament

2002-05-27 Application granted granted Critical

2002-05-27 Publication of DK0939626T3 publication Critical patent/DK0939626T3/da

Links

GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 title abstract 3
229960000600 milnacipran Drugs 0.000 title abstract 3
230000002035 prolonged effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
229920002472 Starch Chemical class 0.000 abstract 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
229930006000 Sucrose Natural products 0.000 abstract 1
239000011230 binding agent Substances 0.000 abstract 1
235000013681 dietary sucrose Nutrition 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000004531 microgranule Substances 0.000 abstract 1
239000004005 microsphere Substances 0.000 abstract 1
229920000642 polymer Polymers 0.000 abstract 1
239000008107 starch Chemical class 0.000 abstract 1
235000019698 starch Nutrition 0.000 abstract 1
229960004793 sucrose Drugs 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Polishing Bodies And Polishing Tools (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK97938949T 1996-08-28 1997-08-26 Galenisk form til forlænget frigivelse af milnacipran DK0939626T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9610528A FR2752732B1 (fr)	1996-08-28	1996-08-28	Forme galenique a liberation prolongee de milnacipran
PCT/FR1997/001525 WO1998008495A1 (fr)	1996-08-28	1997-08-26	Forme galenique a liberation prolongee de milnacipran

Publications (1)

Publication Number	Publication Date
DK0939626T3 true DK0939626T3 (da)	2002-05-27

Family

ID=9495256

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97938949T DK0939626T3 (da)	1996-08-28	1997-08-26	Galenisk form til forlænget frigivelse af milnacipran

Country Status (14)

Country	Link
US (1)	US6699506B1 (de)
EP (1)	EP0939626B1 (de)
JP (2)	JP4549442B2 (de)
CN (1)	CN1108791C (de)
AT (1)	ATE213629T1 (de)
AU (1)	AU727018B2 (de)
BR (1)	BR9711378A (de)
CA (1)	CA2264238C (de)
DE (1)	DE69710757T2 (de)
DK (1)	DK0939626T3 (de)
ES (1)	ES2171991T3 (de)
FR (1)	FR2752732B1 (de)
PT (1)	PT939626E (de)
WO (1)	WO1998008495A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19928312A1 (de) *	1999-06-16	2000-12-21	Schering Ag	Arzneimittelzubereitung mit verzögerter Wirkstoffabgabe
FR2830447B1 (fr) *	2001-10-09	2004-04-16	Flamel Tech Sa	Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) *	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6602911B2 (en)	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
US6635675B2 (en)	2001-11-05	2003-10-21	Cypress Bioscience, Inc.	Method of treating chronic fatigue syndrome
MXPA04009968A (es) *	2002-04-09	2004-12-13	Flamel Tech Sa	Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60323474D1 (de) *	2002-04-09	2008-10-23	Flamel Tech Sa	Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US20040132826A1 (en) *	2002-10-25	2004-07-08	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
CA2503121A1 (en) *	2002-10-25	2004-05-13	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
US20060003004A1 (en) *	2002-10-25	2006-01-05	Collegium Pharmaceutical, Inc.	Pulsatile release compositions of milnacipran
US7704527B2 (en)	2002-10-25	2010-04-27	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
US20060024366A1 (en) *	2002-10-25	2006-02-02	Collegium Pharmaceutical, Inc.	Modified release compositions of milnacipran
JP2006515008A (ja) *	2003-01-28	2006-05-18	コレギウムファーマシューティカル，インコーポレイテッド	経口投与のためのミルナシプランの多粒子状組成物
FR2851163B1 (fr)	2003-02-14	2007-04-27		Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2004075886A1 (fr) *	2003-02-14	2004-09-10	Pierre Fabre Medicament	Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament
US8309128B2 (en)	2005-06-10	2012-11-13	Pierre Fabre Medicament	Stabilized milnacipran formulation
US7994220B2 (en)	2005-09-28	2011-08-09	Cypress Bioscience, Inc.	Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080319083A1 (en) *	2006-01-27	2008-12-25	Asahi Kasei Pharma Corporation	Medicine for transnasal administration
WO2008109462A2 (en) *	2007-03-02	2008-09-12	Farnam Companies, Inc.	Sustained release pellets comprising wax-like material
CN101301283B (zh) *	2007-05-10	2011-04-06	上海医药工业研究院	一种米那普仑的经鼻脑转运组合物
EP2110129A1 (de)	2008-04-18	2009-10-21	Pierre Fabre Medicament	Verwendung von Enanotimer (1S, 2R) Milnacipran-Hydrochlorid zur präventiven Behandlung von Suizidverhalten bei depressiven Patienten
AU2009289464B2 (en) *	2008-09-04	2015-12-10	Farnam Companies, Inc.	Chewable sustained release formulations
DK3045043T3 (da)	2009-02-26	2020-08-03	Relmada Therapeutics Inc	Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
US20100239681A1 (en) *	2009-03-20	2010-09-23	Biokey, Inc.	Controlled Release Particulates Containing Water-Insoluble Drug
FR2943546A1 (fr) *	2009-03-31	2010-10-01	Nouveaux Produits Pharma Sas	Excipient pharmaceutique fonctionnalise ameliorant la biodisponibilite de substances actives peu solubles, microgranules l'incorporant.
FR2945449B1 (fr) *	2009-05-15	2012-10-05	Pf Medicament	Procede d'impregnation par co2 supercritique
US9173845B2 (en)	2009-08-05	2015-11-03	Lupin Limited	Controlled release pharmaceutical compositions of milnacipran
WO2011057176A1 (en) *	2009-11-06	2011-05-12	Forest Laboratories Holding Limited	Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
CA2790933A1 (en) *	2010-01-14	2011-07-21	Forest Laboratories Holdings Limited	Stable dosage forms of levomilnacipran
WO2011107922A2 (en)	2010-03-04	2011-09-09	Ranbaxy Laboratories Limited	Extended release composition of milnacipran
WO2011107921A2 (en)	2010-03-04	2011-09-09	Ranbaxy Laboratories Limited	Modified release composition of milnacipran
EP2611435A2 (de)	2010-08-30	2013-07-10	Lupin Limited	Pharmazeutische retard-zusammensetzungen aus milnacipran
FR2978350B1 (fr)	2011-07-28	2013-11-08	Pf Medicament	Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN102793683B (zh) *	2012-09-04	2013-04-17	海南康虹医药科技开发有限公司	一种含左旋米那普仑的缓释组合物及其制备方法
CN105050708A (zh)	2012-11-14	2015-11-11	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
JP6186139B2 (ja) *	2013-03-08	2017-08-23	杏林製薬株式会社	口腔内速崩壊性錠剤
CN105769823A (zh) *	2014-12-24	2016-07-20	上海星泰医药科技有限公司	一种左旋盐酸米那普仑缓释胶囊及其制备方法
EP3167879A1 (de) *	2015-11-10	2017-05-17	Evonik Technochemie GmbH	Aktives abgabesysteme bei magenretention
CN110711185A (zh) *	2018-07-11	2020-01-21	北京万全德众医药生物技术有限公司	左旋米那普仑缓释胶囊
JP7315383B2 (ja) *	2019-06-27	2023-07-26	株式会社Ｓｃｒｅｅｎホールディングス	インクジェット用水性組成物及び固体製剤
CN114569566A (zh) *	2020-12-02	2022-06-03	四川科瑞德制药股份有限公司	一种盐酸米那普仑制剂的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2508035A1 (fr) *	1981-06-23	1982-12-24	Fabre Sa Pierre	Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
JPS58180481A (ja)	1982-04-15	1983-10-21	Kyowa Hakko Kogyo Co Ltd	新規なピペリジン誘導体
FR2581060B1 (fr) *	1985-04-25	1988-07-01	Pf Medicament	Procede industriel d'obtention du midalcipran
FR2581059B1 (fr) *	1985-04-25	1988-04-22	Pf Medicament	Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z)
US5026560A (en) *	1987-01-29	1991-06-25	Takeda Chemical Industries, Ltd.	Spherical granules having core and their production
FI95572C (fi)	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
FR2640972B1 (de) *	1988-12-28	1991-04-19	Pf Medicament
CA2007181C (en) *	1989-01-06	1998-11-24	Angelo Mario Morella	Sustained release pharmaceutical composition
JP2807577B2 (ja)	1990-06-15	1998-10-08	エーザイ株式会社	環状アミド誘導体
FR2677019B1 (fr)	1991-05-27	1994-11-25	Pf Medicament	Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
GB9113872D0 (en) *	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
US5160742A (en) *	1991-12-31	1992-11-03	Abbott Laboratories	System for delivering an active substance for sustained release
PT640081E (pt)	1992-03-31	2000-05-31	Glaxo Group Ltd	Derivados de fenil-carbamatos e fenil-ureias substituidos sua preparacao e sua utilizacao como antagonistas 5-ht4
ATE217789T1 (de) *	1992-06-04	2002-06-15	Smithkline Beecham Corp	Angenehm schmeckende pharmazeutische zusammensetzungen
CA2134038C (en) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
US5910319A (en) *	1997-05-29	1999-06-08	Eli Lilly And Company	Fluoxetine enteric pellets and methods for their preparation and use

1996
- 1996-08-28 FR FR9610528A patent/FR2752732B1/fr not_active Expired - Fee Related
1997
- 1997-08-26 ES ES97938949T patent/ES2171991T3/es not_active Expired - Lifetime
- 1997-08-26 BR BR9711378A patent/BR9711378A/pt not_active Application Discontinuation
- 1997-08-26 DE DE69710757T patent/DE69710757T2/de not_active Expired - Lifetime
- 1997-08-26 DK DK97938949T patent/DK0939626T3/da active
- 1997-08-26 PT PT97938949T patent/PT939626E/pt unknown
- 1997-08-26 JP JP51133798A patent/JP4549442B2/ja not_active Expired - Lifetime
- 1997-08-26 AT AT97938949T patent/ATE213629T1/de active
- 1997-08-26 EP EP97938949A patent/EP0939626B1/de not_active Expired - Lifetime
- 1997-08-26 AU AU41212/97A patent/AU727018B2/en not_active Expired
- 1997-08-26 US US09/254,014 patent/US6699506B1/en not_active Expired - Lifetime
- 1997-08-26 CN CN97198442A patent/CN1108791C/zh not_active Expired - Lifetime
- 1997-08-26 WO PCT/FR1997/001525 patent/WO1998008495A1/fr not_active Ceased
- 1997-08-26 CA CA002264238A patent/CA2264238C/fr not_active Expired - Lifetime
2010
- 2010-03-10 JP JP2010053612A patent/JP5431214B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0939626A1 (de)	1999-09-08
EP0939626B1 (de)	2002-02-27
ES2171991T3 (es)	2002-09-16
WO1998008495A1 (fr)	1998-03-05
FR2752732B1 (fr)	1998-11-20
JP5431214B2 (ja)	2014-03-05
ATE213629T1 (de)	2002-03-15
CA2264238C (fr)	2009-02-24
CN1232387A (zh)	1999-10-20
BR9711378A (pt)	1999-08-17
AU727018B2 (en)	2000-11-30
CA2264238A1 (fr)	1998-03-05
DE69710757T2 (de)	2004-11-04
FR2752732A1 (fr)	1998-03-06
CN1108791C (zh)	2003-05-21
JP2000516946A (ja)	2000-12-19
JP4549442B2 (ja)	2010-09-22
JP2010163447A (ja)	2010-07-29
PT939626E (pt)	2002-07-31
US6699506B1 (en)	2004-03-02
DE69710757D1 (de)	2002-04-04
AU4121297A (en)	1998-03-19

Publication	Publication Date	Title
ES2171991T3 (es)	2002-09-16	Forma galenica de liberacion prolongada de milnacipran.
NO20016108L (no)	2002-01-24	Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
RU94032150A (ru)	1996-11-10	Лекарственное средство с замедленным высвобождением активно-действующего вещества
MX9701465A (es)	1998-04-30	Formulacion de acetaminofeno, de liberacion sostenida.
HK95590A (en)	1990-11-23	Controlled release naproxen and naproxen sodium tablets
DK0923934T3 (da)	2003-11-24	Modified release-matrixformulering af cefaclor og cephalexin
ATE208192T1 (de)	2001-11-15	Formulierungen mit gesteuerter freisetzung für schwerlösliche arzneistoffe
MA24193A1 (fr)	1997-12-31	Procedes pour la preparation de conjugue peg-ifn alpha physiologiquement actif, et pour la preparation de compositions pharmaceutiques le contenant et leur utilisation
AP2002002553A0 (en)	2002-06-30	Hydrogel-driven Drug Dosoge Form.
IL211075A (en)	2012-03-29	Multi-component preparation with irregular release
BR9917012A (pt)	2002-04-16	Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
ATE244002T1 (de)	2003-07-15	Pharmazeutische formulierung mit omeprazol
DE60117801D1 (de)	2006-05-04	Pharmazeutische zusammensetzung mit gesteuerter freigabe und verzögerter absorption
DE68909772D1 (de)	1993-11-11	Diclofenac-Natrium-Arzneizubereitung mit verlängerter Wirkstoffabgabe.
DE60020501D1 (de)	2005-07-07	Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
HRP20010684B1 (hr)	2011-01-31	Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
CA2383212A1 (en)	2001-03-08	Controlled release oral dosage suitable for oral administration
DE60006362D1 (de)	2003-12-11	Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
CA2417887A1 (en)	2002-02-07	Particulate composition of eletriptan
ATE367153T1 (de)	2007-08-15	Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
EE9600202A (et)	1997-06-16	Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
DE69634080D1 (de)	2005-01-27	Mittel zur verhinderung der truebung der vorderen linsenkapsel
ATE256134T1 (de)	2003-12-15	Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
EP0761209A3 (de)	1998-02-04	Ranitidinformulierungen mit gesteuerter Freisetzung
GB9420748D0 (en)	1994-11-30	1,5 benzodiazepine derivatives